Publications & Posters
Publications & Posters
Peer-Reviewed
Scientific Publications and Posters
We continue to validate, strengthen and leverage our single-cell platform with world leaders and pioneers in immunology and cancer research. Our high scientific standards have been validated in numerous peer-reviewed publications and conference presentations.
Papers
We continually author and publish advancements in our work through high impact peer-reviewed journals
Presentation / Posters
We proudly showcase our work through scientific posters and presentation as top conferences
HiFiBio Therapeutics announced a publication in Science Advances with its collaborators at Nankai University, ShanghaiTech University, and Jiao Tong University about the development of a high-throughput droplet-based approach to identify novel antibodies with functional readouts beyond simple binding.
Mining the antibody repertoire of plasma cells and plasmablasts could enable the discovery of useful antibodies for therapeutic or research purposes1.
The Nature Genetics publication describes a novel high-throughput single-cell ChIP-seq approach to studying heterogeneity of chromatin states within complex biological systems. Our proprietary single-cell CelliGO platform and unique DIS capabilities were used to probe why certain disease cells are resistant to available therapeutics.
Guiding principles of value creation through collaborative innovation in pharmaceutical research HiFiBiO CEO Liang Schweizer and COO Jeff He outline the importance of breaking down common barriers in collaborations, propose four guiding principles for such co-operation and offer a framework to reach value inflection points quicker.
The Nature Biotechnology manuscript details DropMap, “a powerful and elegant technology for the phenotypic analysis of antibody-secreting cells (ASCs) at the single-cell level with unprecedented throughput and resolution.” This droplet microfluidics approach was developed with collaborators from ESPCI and Institut Pasteur.
Presenters: Ross Fulton, Jinping Gan, Yun-Yueh Lu, Julianna Crivello, Zachery Duda, Zhiyuan Wang, Rebecca Silver, Alexandra Staskus, Charina Ortega, Sami Ellouze, Carine George, Sophie Foulon, Wenhua Xu, Xing Cai, Joyce Pi, Dean Lee, Monika Manne, Ruina Jin, Yuan Wang, Hongkai Zhang, Nicola Beltraminelli, Francisco Adrian, Robert Petit, Liang Schweizer, Andreas Raue HFB301001 is being developed … Continued
Presenters: Germain Margall, Muriel David, Julie Prigent, Dean Lee, Wenhua Xu, Joyce Pi, Xing Cai, Tengfei Wang, Ouyang Li, He Zhou, Andreas Raue, Nicola Beltraminelli, Mingjie Chen, Jia Wu, Mingfang Feng, Angelo Paci, Julia Delahousse, Véronique Saada, Stéphane de Botton, Pierre Busson, Stephanie Beq, Francisco Adrian, Liang Schweizer, Yun-Yueh Lu HFB2009 program focuses on developing … Continued
Presenters: Shuo Wei, Ross Fulton, Yun-Yueh Lu, Qian Zhang, He Zhou, Andreas Raue, Mingjie Chen, Wenhua Xu, Xing Cai, Juliana Crivello, Zachary Duda, Zhiyuan Wang, Rebecca Silver, Alexandra Staskus, Charina Ortega, Sami Ellouze, Carine George, Sophie Foulon, Dean Lee, Monika Manne, Nicola Beltraminelli, Jinping Gan, Francisco Adrian, Liang Schweizer, Jennifer Watkins-Yoon HFB200301 is an anti-TNFR2 … Continued
Presenters: Ayrin Kök, Germain Margallducos, Stephanie Beq, Clarisse Monchecourt, Hombline Poullain, Muriel David, Sami Ellouze, Carine George, Mingjie Chen, Yun-Yueh Lu, Juying Li, Qian Zhang, Jean Wang, Adam Woolfe, Louise Gody, Francisco Adrian, Liang Schweizer, Nicola Beltraminelli HFB1002 program focuses on the development of monoclonal antibodies against human CXCR5 as a novel treatment for B-cell … Continued
Presenters: Roshan Kumar, PhD, Senior Director, Head of Discovery Biology and US External Innovation and Yun-Yueh Lu, PhD, Project Leader, Principal Scientist, Disease Biology HFB2009 program focuses on developing anti-Gal-9 neutralizing antibodies as a potential first-in-class treatment for AML and solid tumors, both as a single agent and a combination therapy. More information about these … Continued
Presenters: Francisco Adrian, PhD, Senior Vice President, Head of Research and Shuo Wei, PhD, Project Leader, Principal Scientist, Disease Biology HFB200301 is an anti-TNFR2 monoclonal antibody being developed as a potential first-in-class therapeutic for the treatment of biomarker-selected patients with advanced cancer. More information about these and other programs in the HiFiBiO Therapeutics pipeline is … Continued
Presenters: Andreas Raue, PhD, Project Leader, Senior Director, Head of Drug Intelligent Science (DIS™) at HiFiBiO Therapeutics and Robert Petit, PhD, Senior Scientific Advisor HFB301001 is being developed as a potential novel treatment option for cancer coupled with a patient stratification biomarker in solid tumor indications. More information about these and other programs in the … Continued
